Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure

Farid A K M Ahmed, K. Hegazy, Priya Chaudhary, S. C. Sharma

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Brimonidine, a selective α2-adrenoceptor agonist, has recently been shown to be neuroprotective as it significantly improves survival of retinal ganglion cells (RGCs) after calibrated optic nerve injury in rats. In the present study, we examined the effect of brimonidine (α2-adrenoceptor agonist) on RGC survival after increased intraocular pressure (IOP) in adult rats. RGCs were prelabeled by bilateral tectal injection of 5% Fluoro-Gold (FG). Two days later, unilaterally IOP was increased 2.2-2.5 times (28-30.5 mmHg) that of the normal pressure (12.5-14.5 mmHg) by cauterization of three episcleral veins. The elevated IOP was maintained throughout the duration of the experiment. Rats were treated intraperitoneally with brimonidine (1 mg/kg) or phosphate-buffered saline (PBS) once per week beginning either before (group A) or after (group B) increasing the IOP. Another group of rats was left as the control with elevated IOP but without any brimonidine/PBS treatment. Rats were euthanized at 3, 4 and 5 weeks after IOP elevation. Identifiable RGCs were counted and compared between control and experimental groups. Brimonidine significantly protected RGCs from elevated IOP-induced cell death. In control rats with three-vein cauterization, there was 5-6% cell death per week. Almost all RGCs were protected following brimonidine treatment for 3 weeks both in groups A and B. At 4 weeks, there was 4.5% cell death in group A and 6.5% in group B. At 5 weeks, cell death was 5.9% in group A and 6.2% in group B. The difference in cell death in groups A and B was insignificant. No significant differences were observed between PBS-treated and control groups. No significant changes in elevated IOP was found after brimonidine or PBS treatment when compared with the nontreated control group. Although pressure remained elevated throughout the length of the experiment, 3 weeks later the amount of cell death gradually increased in brimonidine-treated animals.

Original languageEnglish (US)
Pages (from-to)133-139
Number of pages7
JournalBrain Research
Volume913
Issue number2
DOIs
StatePublished - Sep 21 2001
Externally publishedYes

Fingerprint

Retinal Ganglion Cells
Neuroprotective Agents
Intraocular Pressure
Cell Death
Phosphates
Cautery
Adrenergic Receptors
Control Groups
Veins
Optic Nerve Injuries
Pressure
Brimonidine Tartrate
Cell Survival
Therapeutics
Injections

Keywords

  • α-Agonist
  • Adrenoceptor
  • Brimonidine
  • Cell death
  • Hypertensive eye
  • Neuroprotection
  • Retinal ganglion cell

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. / Ahmed, Farid A K M; Hegazy, K.; Chaudhary, Priya; Sharma, S. C.

In: Brain Research, Vol. 913, No. 2, 21.09.2001, p. 133-139.

Research output: Contribution to journalArticle

@article{f1814851fc0947638ceb43b012bcd938,
title = "Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure",
abstract = "Brimonidine, a selective α2-adrenoceptor agonist, has recently been shown to be neuroprotective as it significantly improves survival of retinal ganglion cells (RGCs) after calibrated optic nerve injury in rats. In the present study, we examined the effect of brimonidine (α2-adrenoceptor agonist) on RGC survival after increased intraocular pressure (IOP) in adult rats. RGCs were prelabeled by bilateral tectal injection of 5{\%} Fluoro-Gold (FG). Two days later, unilaterally IOP was increased 2.2-2.5 times (28-30.5 mmHg) that of the normal pressure (12.5-14.5 mmHg) by cauterization of three episcleral veins. The elevated IOP was maintained throughout the duration of the experiment. Rats were treated intraperitoneally with brimonidine (1 mg/kg) or phosphate-buffered saline (PBS) once per week beginning either before (group A) or after (group B) increasing the IOP. Another group of rats was left as the control with elevated IOP but without any brimonidine/PBS treatment. Rats were euthanized at 3, 4 and 5 weeks after IOP elevation. Identifiable RGCs were counted and compared between control and experimental groups. Brimonidine significantly protected RGCs from elevated IOP-induced cell death. In control rats with three-vein cauterization, there was 5-6{\%} cell death per week. Almost all RGCs were protected following brimonidine treatment for 3 weeks both in groups A and B. At 4 weeks, there was 4.5{\%} cell death in group A and 6.5{\%} in group B. At 5 weeks, cell death was 5.9{\%} in group A and 6.2{\%} in group B. The difference in cell death in groups A and B was insignificant. No significant differences were observed between PBS-treated and control groups. No significant changes in elevated IOP was found after brimonidine or PBS treatment when compared with the nontreated control group. Although pressure remained elevated throughout the length of the experiment, 3 weeks later the amount of cell death gradually increased in brimonidine-treated animals.",
keywords = "α-Agonist, Adrenoceptor, Brimonidine, Cell death, Hypertensive eye, Neuroprotection, Retinal ganglion cell",
author = "Ahmed, {Farid A K M} and K. Hegazy and Priya Chaudhary and Sharma, {S. C.}",
year = "2001",
month = "9",
day = "21",
doi = "10.1016/S0006-8993(01)02759-7",
language = "English (US)",
volume = "913",
pages = "133--139",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure

AU - Ahmed, Farid A K M

AU - Hegazy, K.

AU - Chaudhary, Priya

AU - Sharma, S. C.

PY - 2001/9/21

Y1 - 2001/9/21

N2 - Brimonidine, a selective α2-adrenoceptor agonist, has recently been shown to be neuroprotective as it significantly improves survival of retinal ganglion cells (RGCs) after calibrated optic nerve injury in rats. In the present study, we examined the effect of brimonidine (α2-adrenoceptor agonist) on RGC survival after increased intraocular pressure (IOP) in adult rats. RGCs were prelabeled by bilateral tectal injection of 5% Fluoro-Gold (FG). Two days later, unilaterally IOP was increased 2.2-2.5 times (28-30.5 mmHg) that of the normal pressure (12.5-14.5 mmHg) by cauterization of three episcleral veins. The elevated IOP was maintained throughout the duration of the experiment. Rats were treated intraperitoneally with brimonidine (1 mg/kg) or phosphate-buffered saline (PBS) once per week beginning either before (group A) or after (group B) increasing the IOP. Another group of rats was left as the control with elevated IOP but without any brimonidine/PBS treatment. Rats were euthanized at 3, 4 and 5 weeks after IOP elevation. Identifiable RGCs were counted and compared between control and experimental groups. Brimonidine significantly protected RGCs from elevated IOP-induced cell death. In control rats with three-vein cauterization, there was 5-6% cell death per week. Almost all RGCs were protected following brimonidine treatment for 3 weeks both in groups A and B. At 4 weeks, there was 4.5% cell death in group A and 6.5% in group B. At 5 weeks, cell death was 5.9% in group A and 6.2% in group B. The difference in cell death in groups A and B was insignificant. No significant differences were observed between PBS-treated and control groups. No significant changes in elevated IOP was found after brimonidine or PBS treatment when compared with the nontreated control group. Although pressure remained elevated throughout the length of the experiment, 3 weeks later the amount of cell death gradually increased in brimonidine-treated animals.

AB - Brimonidine, a selective α2-adrenoceptor agonist, has recently been shown to be neuroprotective as it significantly improves survival of retinal ganglion cells (RGCs) after calibrated optic nerve injury in rats. In the present study, we examined the effect of brimonidine (α2-adrenoceptor agonist) on RGC survival after increased intraocular pressure (IOP) in adult rats. RGCs were prelabeled by bilateral tectal injection of 5% Fluoro-Gold (FG). Two days later, unilaterally IOP was increased 2.2-2.5 times (28-30.5 mmHg) that of the normal pressure (12.5-14.5 mmHg) by cauterization of three episcleral veins. The elevated IOP was maintained throughout the duration of the experiment. Rats were treated intraperitoneally with brimonidine (1 mg/kg) or phosphate-buffered saline (PBS) once per week beginning either before (group A) or after (group B) increasing the IOP. Another group of rats was left as the control with elevated IOP but without any brimonidine/PBS treatment. Rats were euthanized at 3, 4 and 5 weeks after IOP elevation. Identifiable RGCs were counted and compared between control and experimental groups. Brimonidine significantly protected RGCs from elevated IOP-induced cell death. In control rats with three-vein cauterization, there was 5-6% cell death per week. Almost all RGCs were protected following brimonidine treatment for 3 weeks both in groups A and B. At 4 weeks, there was 4.5% cell death in group A and 6.5% in group B. At 5 weeks, cell death was 5.9% in group A and 6.2% in group B. The difference in cell death in groups A and B was insignificant. No significant differences were observed between PBS-treated and control groups. No significant changes in elevated IOP was found after brimonidine or PBS treatment when compared with the nontreated control group. Although pressure remained elevated throughout the length of the experiment, 3 weeks later the amount of cell death gradually increased in brimonidine-treated animals.

KW - α-Agonist

KW - Adrenoceptor

KW - Brimonidine

KW - Cell death

KW - Hypertensive eye

KW - Neuroprotection

KW - Retinal ganglion cell

UR - http://www.scopus.com/inward/record.url?scp=0035929473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035929473&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(01)02759-7

DO - 10.1016/S0006-8993(01)02759-7

M3 - Article

C2 - 11549376

AN - SCOPUS:0035929473

VL - 913

SP - 133

EP - 139

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -